Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects. Read more.
The June 2012 Newsletter is available by clicking here Some of the content: Wake Up call Breakfast Dr. Uri Lindner at July 25, 2012 Scotiabank Awareness Night Two Dieticians speaks at March Scotiabank Awareness Night Dr. Singal speaks at May Scotiabank Awareness Night Meet Philip Ng PCCN Conference – Regina Words from Ken Hunter PCCN-Toronto makes donations to 3 hospitals On-going Projects for 2012 The PCCN-Toronto Board of Directors (including photo)
I got a call from a friend last year. He had prostate cancer and wanted some help thinking through what to do. He had gone to his doctors for the details about his physical condition. He was calling me for help dealing with the other condition he knew he was facing — excessive fear of this dreaded disease that sometimes does more harm than good, what some have called “cancer phobia.” Read More
CHICAGO—Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer (PCa), but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More